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Background: Cardiovascular risk factors (CVRF) may cluster in type 1 diabetes, analogously to the metabolic
syndrome described in type 2 diabetes. The threshold of HbA1c above which lipid variables start changing behavior
is unclear. This study aims to 1) assess the behavior of dyslipidemia according to HbA1c values; 2) detect a
threshold of HbA1c beyond which lipids start to change and 3) compare the clustering of lipids and other non-lipid
CVRF among strata of HbA1c individuals with type 1 diabetes.
Methods: Effects of HbA1c quintiles (1st: ≤7.4%; 2nd: 7.5-8.5%; 3rd: 8.6-9.6%; 4th: 9.7-11.3%; and 5th: >11.5%) and
covariates (gender, BMI, blood pressure, insulin daily dose, lipids, statin use, diabetes duration) on dyslipidemia were
studied in 1275 individuals from the Brazilian multi-centre type 1 diabetes study and 171 normal controls.
Results: Body size and blood pressure were not correlated to lipids and glycemic control. OR (99% CI) for high-LDL
were 2.07 (1.21-3.54) and 2.51 (1.46-4.31), in the 4th and 5th HbA1c quintiles, respectively. Hypertriglyceridemia
increased in the 5th quintile of HbA1c, OR 2.76 (1.20-6.37). OR of low-HDL-cholesterol were 0.48 (0.24-0.98) and 0.41
(0.19-0.85) in the 3rd and 4th HbA1c quintiles, respectively. HDL-cholesterol correlated positively (0.437) with HbA1c
in the 3rd quintile. HDL-cholesterol and insulin dose correlated inversely in all levels of glycemic control.
Conclusions: Correlation of serum lipids with HbA1c is heterogeneous across the spectrum of glycemic control in
type 1 diabetes individuals. LDL-cholesterol and triglycerides worsened alongside HbA1c with distinct thresholds.
Association of lower HDL-cholesterol with higher daily insulin dose is consistent and it points out to a role of
exogenous hyperinsulinemia in the pathophysiology of the CVRF clustering. These data suggest diverse
pathophysiological processes depending on HbA1c, refuting a unified explanation for cardiovascular risk in
type 1 diabetes.
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Fatal cardiovascular disease before 40 years old shows an
almost 20-fold increase in patients with type 1 diabetes
compared with non-diabetic individuals [1]. Dyslipidemia
is a key cardiovascular risk factor (CVRF) in type 1 dia-
betes, with tighter treatment goals than the non-diabetic
population [2]. Nevertheless, differences in the behavior of
dyslipidemia in type 1 diabetes are not only quantitative
but qualitative when compared with non-diabetic indivi-
duals. Although CVRF increase in the general population
alongside increasing glucometabolic disturbances [3],
some evidence point to lipid profile being globally wor-
sened in type 1 diabetes, with lower HDL-cholesterol and
higher LDL and triglycerides [4], whereas others have
demonstrated higher HDL-cholesterol levels [5], albeit
with a less protective profile [6]. Besides, some studies
have shown lipids to take a less important role in the
increased CV risk of type 1 diabetes than other factors
[7,8]. Furthermore, type 1 diabetes seems to attenuate or
even erase gender differences in cardiovascular (CV)
disease [5]. Although observational studies have shown
improved lipid profile with better glycemic control [9],
there is uncertainty about the role of improved glycemic
control in the prevention of macrovascular disease in
these patients, as there are no well-defined thresholds of
HbA1c beyond which lipid levels begin to change in type 1
diabetes [4,10,11].
Clustering of CVRF may occur in type 1 diabetes
[12,13], analogously to the one known as metabolic syn-
drome in type 2 diabetes, but there is a different multi-
factorial pathophysiology for the clustering in each of
the two major types of diabetes [12,14,15]. Currently, a
unified explanation for the buildup of CVRF with the
progression of type 1 diabetes is debatable as a patho-
logical entity, regarding its prognostic importance. In
addition to the intricate interaction among CVRF, hyper-
insulinemia caused by exogenous insulin replacement
can add to the complexity of this scenario.
Factor analysis (FA) is a statistical method that pro-
vides correlation coefficients (called factor loadings) of
studied variables with latent variables called factors, ra-
ther than among variables themselves. It has been fre-
quently used to gain insight on the clustering of CVRF
of type 2 diabetes [16]. This method has been criticized
for its low reproducibility, since results depend on which
variables are entered in the models [17]. While some
FAs have suggested the existence of a single factor re-
sponsible for the clustering of CVRF in type 2 diabetes
[18,19], others have shown the existence of a lipid factor
(correlated to HDL-cholesterol and triglycerides), an in-
sulin resistance (IR) factor (blood glucose and insulin),
and a body size factor (BMI and abdominal circumfer-
ence) in both non-diabetic and type 2 diabetic indivi-
duals [20,21]. Others have shown association of lipidvariables with glycemic control [22], albeit not employ-
ing HbA1c. In type 1 diabetes, a previous FA has found
roughly the same type 2 diabetes classical factors, but
without assessing glycemic control in these models [23].
In another FA of CVRF in individuals with type 1 diabetes,
we previously showed HbA1c to have a continuous correl-
ation with lipid variables and to disrupt the classical lipid
factor when employed [24], suggesting the grouping of
lipids and CVRF to vary across the wide glycemic control
range displayed by individuals with type 1 diabetes. Since
FA results are heavily influenced by which variables are
entered in the models, the question of how glucose metab-
olism influences clustering of lipids and other CVRF is still
open in type 1 diabetes.
We hypothesize that the heterogeneity in the cluster-
ing of lipids and other CVRF seems to arise partly from
the heterogeneity in the concept of the cluster itself in
individuals with diabetes mellitus, as recently discussed
by Reaven [14]. Given the different results obtained in
FAs of CVRF clusters in different populations [25], the
clustering of lipid abnormalities and other non-lipid
CVRF may not have the same meaning in different clin-
ical settings.
In this study, we aimed to: 1) assess the behavior of dys-
lipidemia according to HbA1c values individuals with type
1 diabetes; 2) detect a threshold of HbA1c beyond which
lipids start to change; 3) compare the clustering of lipids
and other non-lipid CVRF among strata of HbA1c.
Methods
Data from the Brazilian Type 1 Diabetes Study Group (Braz-
Diab1SG) have been analyzed. In brief, BrazDiab1SG is a
multi-centre cross-sectional study of a population-based
sample representative of individuals with type 1 diabetes
from all 5 major geographical regions of Brazil, totaling
3591 patients. Research methodology has been described in
detail elsewhere [26]. Individuals with available data on
HbA1c measured by a NGSP standardized method (with
normal range 4-6%) and age equal or older than 12 years
old have been selected for this study, resulting in a sample
of 1275 patients.
The following variables were studied: gender, age,
diabetes duration (log-transformed to approximate normal
distribution), BMI, mean blood pressure (MBP), calculated
as the sum of one-third of systolic blood pressure and two-
thirds of diastolic blood pressure, total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides, HbA1c, total
insulin dose, statin use, smoking, microalbuminuria, and
presence of nephropathy (defined as any degree of
abnormality from macroalbuminuria to decreased renal
function, but excluding overt renal failure). Lipids have
been dichotomized according to the NCEP-ATP III criteria
[27]: low-HDL-cholesterol was defined as HDL-cholesterol
≤ 1.04 mmol/L (≤ 40 mg/dL in conventional units), high-
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(≥ 100mg/dL), and hypertriglyceridemia as triglycerides
≥ 1.7 mmol/L (≥150 mg/dL). HbA1c values have been
divided in quintiles. Continuous variables have been com-
pared using ANOVA with Scheffe’s post-hoc testing. Ca-
tegorical variables have been compared by Chi-square.
Low-HDL-cholesterol, high-LDL-cholesterol, and hyper-
triglyceridemia have been entered as dependent variables
in forward logistic regression models, with HbA1c quin-
tiles as independent categorical covariate, using the 1st
quintile as reference category. All other studied variables
have been entered in different combinations in continuous
or categorical form, the best fit for each model being
chosen according to Nagelkerke pseudo-R-squared values
and Hosmer-Lemeshow goodness-of-fit test. Values were
recorded as OR (99% CI).
Exploratory factor analyses of age, diabetes duration
(log-transformed), total daily insulin dose, MBP, HDL-chol-
esterol, triglycerides, and HbA1c have been performed sep-
arately by quintiles of HbA1c. Oblique rotation has been
employed in order to achieve simple structure. Factor ana-
lysis has also been performed in 171 non-diabetic controls,
utilizing the same variables as in type 1 diabetic individuals,
except for serum fasting insulin in place of insulin dose to
account for the role of hyperinsulinemia/IR and theTable 1 Clinical and laboratory characteristics of individuals w
1st 2nd
≤ 7.4% 7.5 - 8.5%
n 255 258
Age (years) 26.1 ± 12.0 26.7 ± 11.6
Duration of diabetes (years) 12.2 ± 10.1 12.9 ± 8.7
Total daily insulin dose (U) 45.6 ± 19.9 52.7 ± 22.8
BMI (kg/m2) 22.5 ± 3.7 23.2 ± 3.9
HbA1c (%) 6.6 ± 0.64 8.0 ± 0.32
Fasting plasma glucose (mmol/L) 7.77 ± 4.12 9.30 ± 5.23
Mean Blood Pressure (mmHg) 101.9 ± 12.8 100.9 ± 12.9
Total cholesterol (mmol/L) 4.08 ± 1.03 4.21 ± 1.05
HDL-cholesterol (mmol/L) 1.34 ± 0.46 1.38 ± 0.38
LDL-cholesterol (mmol/L) 2.31 ± 0.78 2.42 ± 0.79
Triglycerides (mmol/L) 0.92 ± 0.64 0.95 ± 0.72
Male gender (%) 49.0 46.9
Statin users (%) 10.2 14.7
Hypertriglyceridemia (%) 7.6 8.5
Low HDL-cholesterol (%) 21.8 14.0
High LDL-cholesterol (%) 31.6 34.2
Microalbuminuria (%) 44.7 56.6
Smokers (%) 4.7 6.6
a 5th quintile vs. all others; b 5th vs. 1st, 2nd, 3rd and 2nd vs. 4th quintiles; c 1st vs.
and 4th quintiles; e all pairwise comparisons; f 5th vs. all others; 1st vs. 3rd, 4th, 5th
quintiles; h 5th vs. 1st, 2nd, and 3rd; 4th vs. 1st quintiles; i 4 degrees-of-freedom sigexclusion of diabetes duration, which has no correlate par-
ameter in non-diabetic individuals. Baseline characteristics
of this group have been previously described [28].
Statistical analyses have been carried out with SPSS 13.0
for Windows software (SPSS Inc., Chicago, IL, USA).
Graphics have been made in OmniGraphSketcher 1.2.1
(v22.23) for MacOS (The Omni Group, Seattle, WA, USA).
The study was approved by the local Ethics Committee
of each participant institution, as previously described [26].
Results
Baseline characteristics of participants according to
HbA1c quintiles are described in Table 1, first only with
univariate analysis.
Logistic regression models with ORs (99% CI) of dyslipi-
demia (as categorical variables) per HbA1c quintile are
depicted in Figure 1A (low-HDL), B (high-LDL), and C
(hypertriglyceridemia). All models were adjusted for age,
diabetes duration, total daily insulin dose, statin use, BMI,
blood pressure, presence of microalbuminuria and/or
overt nephropathy, and smoking. Low-HDL-cholesterol
was significantly less frequent in the 3rd HbA1c quintile,
with OR 0.48 (0.24-0.98), and in the 4th quintile, with OR
0.41 (0.19-0.85) when compared to the 1st quintile. Covariates
associated to low-HDL-cholesterol were male gender (ORith type 1 diabetes, divided by HbA1c quintiles
HbA1c quintiles
3rd 4th 5th
8.6 - 9.6% 9.7 - 11.4% ≥ 11.5% p
255 255 252
25.2 ± 11.4 23.9 ± 10.5 20.9 ± 9.1 < 0.05a
11.9 ± 7.9 10.5 ± 7.5 8.9 ± 6.4 < 0.05b
55.2 ± 20.0 58.5 ± 21.5 62.1 ± 23.5 < 0.05c
23.1 ± 3.9 22.8 ± 4.4 21.7 ± 3.8 < 0.05d
9.1 ± 0.33 10.5 ± 0.55 13.6 ± 1.77 < 0.05e
10.68 ± 5.81 11.22 ± 5.81 12.96 ± 7.37 < 0.05f
102.1 ± 13.4 101.2 ± 13.2 99.7 ± 12.8 NS
4.34 ± 1.13 4.57 ± 1.01 4.86 ± 1.19 < 0.05g
1.37 ± 0.34 1.43 ± 0.41 1.38 ± 0.37 NS
2.53 ± 0.88 2.67 ± 0.86 2.90 ± 0.99 < 0.05h
1.00 ± 0.72 1.04 ± 0.70 1.31 ± 1.18 < 0.05a
42.7 39.6 36.9 0.034i
10.6 7.5 5.6 0.007i
12.3 13.9 25.2 < 0.001i
12.6 10.0 16.6 0.008i
40.4 50.0 57.2 < 0.001i
51.4 47.5 45.6 < 0.044i
4.7 2.4 6.7 NS
all others, 2nd vs. 4th and 5th, 3rd vs. 5th quintiles; d 5th vs. 2nd, 3rd
; 2nd vs. 4th quintile; g 1st vs. 4th and 5th; 2nd vs. 4th and 5th; 3rd vs. 5th
nificance; NS non-significant.
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Covariates associated with low HDL: OR (99%CI)
Male gender: 1.82 (1.14-2.90)
Total insulin dose (per 1U increase): 1.013 (1.002-1.023)
Triglycerides (per 1 mmol/L increase): 1.614 (1.234-2.111)
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Covariates associated with high LDL: OR (99%CI)
Male gender: 0.687 (0.488-0.966)
Triglycerides (per 1 mmol/L increase): 1.669 (1.282-2.173)
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Covariates associated with hypertriglyceridemia: OR (99%CI)
Male gender: 0.565 (0.329-0.969)
LDL-cholesterol (per 1 mmol/L increase): 2.237 (1.713-2.922)
HDL-cholesterol (per 1 mmol/L increase): 0.474 (0.243-0.926)
C
Figure 1 OR (99% CI) of dyslipidemia according to HbA1c quintile. A. Low-HDL-cholesterol (HDL-cholesterol ≤ 1.04 mmol/L) B. High-LDL
(LDL ≥ 2.59 mmol/L). C. Hypertriglyceridemia (triglycerides ≥ 1.7 mmol/L). All ORs are relative to the reference category (1st quintile).
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http://www.cardiab.com/content/11/1/1561.82 [1.14-2.90]), total insulin dose (OR 1.013 [1.002-1.023]
for each 1U increase), and triglycerides (OR 1.614 [1.234-
2.111] for each 1 mmol/L increase). High-LDL-cholesterol
had significant higher ORs in the 4th and 5th quintiles,
respectively 2.07 (1.21-3.54) and 2.51 (1.46-4.31) when
compared to the 1st quintile. Covariates associated with
high-LDL were male gender (OR 0.687 [0.488-0.966]) and
triglycerides (OR 1.669 [1.282-2.173] per each 1 mmol/L
increase). Hypertriglyceridemia increased only in the 5th
quintile of HbA1c, with OR 2.76 (1.20-6.37). Significant
covariates were male gender (ORs 0.565 [0.329-0.969]),
LDL-cholesterol (2.237 [1.713-2.922] per 1 mmol/L in-
crease), and HDL-cholesterol (0.474 [0.243-0.926] per 1
mmol/L increase). Other covariates were not associated to
dyslipidemia in any of the models. Although the presence
of microalbuminuria was different among HbA1c quintiles
in univariate analysis, this difference was not maintained
in various multivariate models tested.
Factor analysis has extracted three factors uniformly in
all HbA1c quintiles and in the non-diabetic control group.
Factors have been denominated Hyperinsulinemia/IR,
Body Size/Time, and Glucose Metabolism. The three fac-
tors along with factor loadings for significant variables
(those with coefficients above 0.40) are depicted schemat-
ically in Figure 2. The Hyperinsulinemia/IR factor has cor-
related directly with insulin daily dose and inversely with
HDL-cholesterol constantly in all five groups of indivi-
duals with type 1 diabetes. A similar correlation occurred
in normal controls with fasting serum insulin. The Body
Size/Time factor has showed a constant structure of BMI,
age, MBP, and diabetes duration (except in non-diabetic
individuals, in whom this variable is not applicable) in all
six groups. Glucose Metabolism factor showed constant
correlation to HbA1c in all groups, with loadings in the
0.7-0.9 range in all groups, but correlation of lipids withNon-diabetic 
controls
BMI 0.704
Insulin 0.793
HDL -0.487
Age 0.826
BMI 0.528
MBP 0.732
A1C 0.785
Triglycerides -0.650
1st HbA1
c
 quintile
A1C 0.858
Triglycerides -0.466
Age 0.819
BMI 0.579
Diabetes duration 0.788
MBP 0.644
BMI 0.452
Insulin dose 0.767
Triglycerides 0.507
HDL -0.621
Triglycerides 0.645
Insulin dose 0.724
HDL -0.714
Age 0.858
BMI 0.536
Diabetes duration 0.767
MBP 0.630
A1C 0.852
BMI 0.490
2nd HbA1
c
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Body size/
Time
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Figure 2 Comparison of factor structures of CVRF clusters in 171 non
divided by quintiles of HbA1c (signs of correlation coefficients are va
same group).this factor was variable. Of note, in non-diabetic controls
and in the 1st HbA1c quintile, correlations of HbA1c and
triglycerides occurred in opposite directions (i.e., decreas-
ing triglyceride levels with increasing HbA1c). In the 3rd
quintile, correlation of HbA1c, triglycerides, and HDL-
cholesterol occurred in the same direction (simultaneous
increase in HbA1c, triglycerides, and HDL-cholesterol). In
the 4th quintile, triglycerides increased alongside HbA1c.
Discussion
This population-based study showed distinct behavior of
each class of serum lipids according to HbA1c levels in
individuals with type 1 diabetes. The risk of having low
HDL-cholesterol did not show a homogeneous inverse re-
lation to HbA1c, being lower in the middle range of HbA1c
(8.6 to 11.4%) than in HbA1c levels equal or above 11.5%.
The risk of high LDL-cholesterol and triglycerides levels
both showed increase with worsening glycemic control, al-
though in different thresholds of HbA1c. LDL-cholesterol
worsened starting at 9.7% and triglycerides only above an
11.5% HbA1c level. Regarding association with other vari-
ables, HDL-cholesterol showed marked inverse association
with insulin dose. Rather than associating around a con-
stant lipid factor, lipid variables correlated to glycemic con-
trol diversely according to HbA1c level.
Not all previous studies have shown homogeneous be-
havior of HDL-cholesterol in type 1 diabetes. Some have
reported worsening of HDL-cholesterol with poorer gly-
cemic control [4,29], whereas others have demonstrated
better HDL-cholesterol levels in type 1 diabetes when
compared to non-diabetic controls [10,30]. Somehow in
comparisons performed only among individuals with
type 1 diabetes, patients with poorer glycemic control
have also been shown to have a paradoxical elevation of
HDL-cholesterol compared to well-controlled individualsBMI 0.499
Insulin dose 0.811
HDL -0.602
Age 0.835
BMI 0.567
Diabetes duration 0.785
MBP 0.592
A1C 0.743
HDL 0.437
Triglycerides 0.498
3rd  HbA1
c
 quintile
Insulin dose 0.810
HDL -0.577
Age 0.795
BMI 0.674
Diabetes duration 0.770
MBP 0.569
A1C 0.791
Triglycerides 0.669
4th  HbA1
c
 quintile
BMI -0.677
Triglycerides -0.528
Insulin dose -0.663
HDL 0.573
Age 0.861
BMI 0.464
Diabetes duration 0.681
MBP 0.676
A1C 0.882
5th  HbA1
c
 quintile
-diabetic controls and 1275 individuals with type 1 diabetes
lid only to compare variables within the same factor and in the
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count for differences between our findings and existing lit-
erature. Some studies have stratified subgroups in HbA1c
levels as low as 7.5% [11], therefore being unable to assess
differences in lipid behavior in the heterogeneous group of
individuals with HbA1c levels above 7.5. While a lower
threshold of HbA1c around 8% for changing behavior of
HDL-cholesterol may be inferred from previous studies,
an upper threshold is unclear. This also can account for
the finding of worsening HDL-cholesterol with poor gly-
cemic control. The grouping of individuals with inter-
mediate HbA1c levels, who would supposedly have higher
HDL, with individuals with higher HbA1c, who would
have lower HDL-cholesterol values, could result in average
worsening of HDL-cholesterol without accounting for the
heterogeneity in the whole spectrum of glycemic control.
This differentiation is important since there is evidence
that these higher HDL-cholesterol levels can be associated
with higher cardiovascular risk in individuals with type 1
diabetes, lacking the protective effect of high HDL-
cholesterol in non-diabetic individuals [6]. Another im-
portant aspect of low HDL-cholesterol is its relationship
to higher insulin daily doses in type 1 diabetes therapy,
which may indicate a higher insulin resistance back-
ground. Previous studies have shown IR to be a CVRF in
individuals with type 1 diabetes [5]. Low HDL-cholesterol
is traditionally associated to IR and hyperinsulinemia in
non-diabetic individuals, albeit the causal relationship
among these three alterations is unclear. Our findings
show association of higher insulin dose with low HDL-
cholesterol consistently, independently of glycemic con-
trol. In type 1 diabetes, IR is not an established etiological
factor but it can progressively develop after clinical diag-
nosis [32]. Moreover, current insulin therapy methods are
themselves a potential cause of hyperinsulinemia in these
patients. Although the cross-sectional design of our study
precludes any assumption of causality, one could postulate
there is direct relationship between daily insulin doses and
low HDL, without going through IR. The association of
low-HDL-cholesterol with total daily insulin dose, cor-
rected for BMI in the multivariable models (both regres-
sion and FA), could point to a role of IR by augmenting
insulin needs, thus isolating the roles of obesity and ex-
ogenous insulin on HDL, rather than merging them both
by using insulin dose per body weight instead. In this re-
gard, a recent article has shown the insulin concentration
required for 50% suppression of hepatic glucose produc-
tion in a hyperinsulinemic/euglycemic clamp to be almost
two times higher in type 1 diabetes than in controls
adjusted for age, gender, and HbA1c. The authors suggest
that hepatic and skeletal muscle IR in type 1 diabetes is
not explained only by previously known factors [32]. Pre-
vious studies have already suggested the CV risk conferred
by IR to be detached from lipid variables [5].The finding of higher triglyceride levels with worse gly-
cemic control appears to depend also on the mode
patients are stratified for glycemic control. Studies that
have divided patients in two groups with low HbA1c
thresholds have both showed no difference [10] or higher
triglycerides in the higher HbA1c group [11,29,31]. Again,
the stratification of HbA1c in lower levels can group to-
gether individuals with normal and high triglycerides,
without necessarily establishing a threshold. Our data
show a HbA1c threshold for increase in the probability of
hypertrigliceridemia above 11%. This value has not been
clearly established by previous studies and possibly varies
according to diet and population differences.
The inverse relationship of triglycerides and HbA1c in
normal controls and individuals with type 1 diabetes
observed with HbA1c below 7.5 is less well explained al-
though it has been previously demonstrated [11,30,33].
Previous studies hypothesized that more intensive insu-
lin therapy, which is usually the case in well-controlled
patients, can bring lipids to values below those shown by
normal controls. Insulin has effects upon lipid metabol-
ism by stimulating enzymes such as hormone-sensitive
lipase [34]. It is possible that in the normal (non-diabetic
controls) or near-normal (good glycemic control) glu-
cose range the effects of hyperinsulinemia can be more
effective in controlling glucose as a compensatory mech-
anism than normal insulin values, thus mild degrees of
hyperglycemia being associated with better triglyceride
metabolism. A role for portal insulinopenia, as opposed
to systemic hyperinsulinemia, cannot be excluded as well
[35]. Nevertheless, the correlation of triglycerides with
the Hyperinsulinemia/IR factor hypothesized in our FA
still leaves the order in the causal relationship of IR and
hyperinsulinemia open to questioning.
LDL-cholesterol metabolism showed a pattern similar
to triglycerides, although with a lower threshold. This
finding furthermore supports the view that lipids are
influenced by glycemic control of type 1 diabetes in a
complex manner, not interacting with other cardiovascu-
lar risk factors such as blood pressure and obesity analo-
gously to the CVRF cluster of type 2 diabetes.
Clustering of CVRF has been analyzed by factor analysis
in various contexts. Its reproducibility has been criticized,
since many reported models have yielded different results.
Since this statistical technique (or any other, for that mat-
ter) is unable to assess biological plausibility of the models,
one has to take especial care on previous planning of the
analyses rather than in interpreting them. One-factor mod-
els of CVRF clustering are pathophysiologically implaus-
ible, given the multifactorial nature of involved conditions.
The heterogeneity of previous results, therefore, can be
attributed to differences in the populations analyzed and in
the variables entered in the FAs. Glycemic control has not
been frequently assessed previously in the clustering of
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strated correlation of lipids and HbA1c in type 1 diabetes
by means of factor analysis, but without the necessary
statistical power to divide the 520 patients in subgroups
according to HbA1c levels [24]. From this point of view, the
present study is adequately powered to perform the ana-
lyses, once the subgroups have samples above 200 hundred
individuals, considered adequate by most authors [36].
Regarding reproducibility, FA is an adequate method to test
our hypothesis of different clustering of CVRF according to
HbA1c level, since individuals form the same population
have been compared using exactly the same variables.
The most important limitation of our study is its cross-
sectional design, unable to assess temporal relationship
among the various factors studied. Another limitation is
that FA was not performed separately by gender. Gender
significantly influenced the frequency of low-HDL-choles-
terol, high-LDL-cholesterol, and hypertriglyceridemia in the
logistic regression models, but dividing the five quintiles of
HbA1c in ten groups by gender would impair sample power
for performing FA. Another alternative approach would be
using wider intervals of HbA1c to avoid excessive number
of subgroups. In our view, this approach would generate
more heterogeneous groups regarding glycemic control and
would be inadequate to test our hypothesis. Nevertheless,
gender differences in CV risk seem to be attenuated or
even erased in type 1 diabetes [5], making our FA model
without subdividing by gender valid to assess the main hy-
pothesis of this paper. The absence of direct measurements
of IR is also an important limitation, although it wouldn’t
necessarily be feasible in such a large sample.
Conclusions
We present data from a large multi-centre cross-section
study of type 1 diabetes in the Brazilian population, pro-
viding new insight on how glycemic control may influ-
ence behavior of dyslipidemia in type 1 diabetes,
individually for each lipid fraction. Different levels of
HbA1c are significantly associated with change in fasting
lipids, but a threshold of HbA1c beyond which lipid
variables start to change is not homogenous, challenging
the view of CVRF clustering as a single pathophysio-
logical construct in type 1 diabetes. These considerations
are important to decide when medical therapy may be
required to optimize lipid and cardiovascular health be-
sides diet, lifestyle interventions, and glycemic control
level in individuals with type 1 diabetes, sometimes
already at an early age.
Further prospective studies assessing cardiovascular
events and intervention studies to evaluate if glycemic con-
trol also influences response to medical treatment of dysli-
pidemia are warranted to scrutinize the impact of the
present information on actual cardiovascular prognosis of
patients with type 1 diabetes.Abbreviations
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